Cargando…

Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

Detalles Bibliográficos
Autores principales:	Elnaggar, Muhammad, Agte, Sarita, Restrepo, Paula, Ram, Meghana, Melnekoff, David, Adamopoulos, Christos, Stevens, Mark M., Kappes, Katerina, Leshchenko, Violetta, Verina, Daniel, Jagannath, Sundar, Poulikakos, Poulikos I., Parekh, Samir, Laganà, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169501/ https://www.ncbi.nlm.nih.gov/pubmed/37158935 http://dx.doi.org/10.1186/s13045-023-01449-x

Ejemplares similares

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
por: Elnaggar, Muhammad, et al.
Publicado: (2022)

OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
por: Oekelen, Oliver Van, et al.
Publicado: (2021)

Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
por: Bhalla, Sherry, et al.
Publicado: (2021)

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
por: Laganà, Alessandro, et al.
Publicado: (2018)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
por: Verina, Daniel, et al.
Publicado: (2021)

Inhibitors of BRAF dimers using an allosteric site
por: Cotto-Rios, Xiomaris M., et al.
Publicado: (2020)

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
por: Mouhieddine, Tarek H., et al.
Publicado: (2022)

SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
por: Ahmed, Tamer A., et al.
Publicado: (2019)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report
por: Madduri, D., et al.
Publicado: (2021)

CDK4: a master regulator of the cell cycle and its role in cancer
por: Baker, Stacey J., et al.
Publicado: (2022)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
por: Kogan Zajdman, Ariel, et al.
Publicado: (2022)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
por: Aleman, Adolfo, et al.
Publicado: (2022)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jl0ihsn5cvqijeapn2uhlpgqcc